Brokerages Set BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Target Price at $88.00

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has been assigned a consensus rating of “Moderate Buy” from the twenty-three analysts that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, six have given a hold recommendation, fifteen have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $88.00.

Several brokerages recently issued reports on BMRN. Sanford C. Bernstein reduced their price objective on BioMarin Pharmaceutical from $94.00 to $82.00 and set an “outperform” rating for the company in a research note on Tuesday, May 5th. Citigroup lifted their target price on BioMarin Pharmaceutical from $75.00 to $76.00 and gave the company a “buy” rating in a research note on Thursday, July 16th. Bank of America dropped their target price on BioMarin Pharmaceutical from $85.00 to $80.00 and set a “buy” rating on the stock in a report on Tuesday, May 19th. Weiss Ratings lowered shares of BioMarin Pharmaceutical from a “hold (c-)” rating to a “sell (d)” rating in a research report on Tuesday, August 11th. Finally, HC Wainwright raised their price target on shares of BioMarin Pharmaceutical from $50.00 to $60.00 and gave the stock a “neutral” rating in a report on Friday, August 7th.

Institutional Investors Weigh In On BioMarin Pharmaceutical

Institutional investors have recently modified their holdings of the stock. Freestone Grove Partners LP purchased a new position in shares of BioMarin Pharmaceutical during the 2nd quarter valued at $20,839,000. Caisse de depot et placement du Quebec acquired a new position in shares of BioMarin Pharmaceutical in the second quarter worth $70,749,000. Trails Edge Capital Partners LP acquired a new position in shares of BioMarin Pharmaceutical in the second quarter worth $29,296,640,000. Elmind Capital LP purchased a new stake in shares of BioMarin Pharmaceutical during the second quarter worth $2,689,340,000. Finally, ADAR1 Capital Management LLC purchased a new stake in shares of BioMarin Pharmaceutical during the second quarter worth $2,804,000. Institutional investors and hedge funds own 98.71% of the company’s stock.

BioMarin Pharmaceutical Stock Performance

NASDAQ BMRN opened at $67.36 on Wednesday. The firm’s 50 day moving average price is $59.56 and its two-hundred day moving average price is $57.51. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.32 and a current ratio of 2.39. BioMarin Pharmaceutical has a twelve month low of $49.26 and a twelve month high of $70.98. The stock has a market cap of $13.04 billion, a price-to-earnings ratio of 182.05, a PEG ratio of 0.47 and a beta of 0.24.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.95 by $0.25. The company had revenue of $989.71 million during the quarter, compared to analyst estimates of $932.03 million. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%.The company’s revenue for the quarter was up 20.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.44 earnings per share. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Equities analysts anticipate that BioMarin Pharmaceutical will post 4.22 EPS for the current year.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.